Aldeyra Therapeutics, Inc.
ALDX
$4.87
-$0.01-0.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.69M | -9.77M | -9.93M | -15.81M | -15.11M |
| Total Depreciation and Amortization | 63.70K | 62.30K | 60.90K | 64.40K | 63.00K |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 267.30K | -- | -- |
| Total Other Non-Cash Items | 2.36M | -182.40K | 1.88M | 842.00K | 2.75M |
| Change in Net Operating Assets | -1.76M | 1.33M | -4.75M | 2.87M | 4.32M |
| Cash from Operations | -7.02M | -8.56M | -12.47M | -12.04M | -7.97M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.00M | -554.10K | 7.29M | -1.56M | 5.26M |
| Cash from Investing | 25.00M | -554.10K | 7.29M | -1.56M | 5.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -292.50K | -- |
| Issuance of Common Stock | 120.70K | 0.00 | 1.00M | 350.30K | 19.90K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -50.00K | -217.30K |
| Cash from Financing | 120.70K | 0.00 | 1.00M | 7.80K | -197.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.10M | -9.11M | -4.18M | -13.59M | -2.91M |